Clinical Trial Detail

NCT ID NCT02039947
Title Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors GlaxoSmithKline
Indications

melanoma

Therapies

Dabrafenib + Trametinib

Age Groups: adult

Additional content available in CKB BOOST